Carcinoma, Non-Small-Cell Lung Clinical Trials in Washington D.C., District of Columbia

10 studies are recruiting for carcinoma, non-small-cell lung in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

   This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Georgetown University, Washington D.C., District of Columbia

   Locations

   16 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07154290 on ClinicalTrials.gov

2. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   418 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06119581 on ClinicalTrials.gov

3. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

   The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   369 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06890598 on ClinicalTrials.gov

4. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

   The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characteriz…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   110 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05498428 on ClinicalTrials.gov

5. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

   The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MedStar Georgetown University Hospital, Washington D.C., District of Columbia

   Locations

   203 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06667076 on ClinicalTrials.gov

6. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

   The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University ( Site 0036), Washington D.C., District of Columbia

   Locations

   46 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04165070 on ClinicalTrials.gov

7. KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

   This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substu…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Georgetown University ( Site 0036), Washington D.C., District of Columbia

   Locations

   47 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04165798 on ClinicalTrials.gov

8. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

   The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Washington DC Veterans Affairs Medical Center, Washington D.C., District of Columbia

   Locations

   372 in total

   Run by

   Pfizer

   See if you can join NCT06758401 on ClinicalTrials.gov

9. Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

   This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durval…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Locations

   4 in total

   Run by

   Georgetown University

   See if you can join NCT04499053 on ClinicalTrials.gov

10. Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

    This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C., District of Columbia

    Locations

    3 in total

    Run by

    Hackensack Meridian Health

    See if you can join NCT05715229 on ClinicalTrials.gov